|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
JP5646457B2
(ja)
|
2008-04-29 |
2014-12-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
EP3002299A1
(en)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
PE20100054A1
(es)
|
2008-06-03 |
2010-03-03 |
Abbott Lab |
Inmunoglobulina con dominio variable dual
|
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
|
JP5587975B2
(ja)
*
|
2009-04-07 |
2014-09-10 |
ロシュ グリクアート アクチェンゲゼルシャフト |
二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
|
|
US8623358B2
(en)
|
2009-08-29 |
2014-01-07 |
Abbvie Inc. |
Therapeutic DLL4 binding proteins
|
|
AR078254A1
(es)
*
|
2009-09-01 |
2011-10-26 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
MX2012004415A
(es)
*
|
2009-10-15 |
2012-05-08 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
KR20120118002A
(ko)
|
2009-12-08 |
2012-10-25 |
애보트 게엠베하 운트 콤파니 카게 |
망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
|
|
EP2542582A4
(en)
|
2010-03-02 |
2013-12-04 |
Abbvie Inc |
THERAPEUTIC PROTEINS LINKING TO DLL4
|
|
US8735546B2
(en)
|
2010-08-03 |
2014-05-27 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
PH12013500337A1
(en)
|
2010-08-26 |
2017-08-23 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2681242B1
(en)
|
2011-03-01 |
2018-01-24 |
Amgen Inc. |
Sclerostin and dkk-1 bispecific binding agents
|
|
JP2014519338A
(ja)
|
2011-06-16 |
2014-08-14 |
ノバルティス アーゲー |
治療薬として使用される可溶性タンパク質
|
|
US9120870B2
(en)
|
2011-12-30 |
2015-09-01 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-13 and IL-17
|
|
WO2013101993A2
(en)
*
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
EP3369746A1
(en)
|
2012-01-27 |
2018-09-05 |
AbbVie Deutschland GmbH & Co KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
|
EP2847215A1
(en)
*
|
2012-05-07 |
2015-03-18 |
Synthes GmbH |
Methods and devices for treating intervertebral disc disease
|
|
SG10202006507XA
(en)
|
2012-05-30 |
2020-08-28 |
Chugai Pharmaceutical Co Ltd |
Target-tissue-specific antigen-binding molecule
|
|
WO2014037811A2
(en)
|
2012-09-07 |
2014-03-13 |
The Governors Of The University Of Alberta |
Methods and compositions for diagnosis of inflammatory liver disease
|
|
AU2013337775B2
(en)
|
2012-11-01 |
2017-03-30 |
Abbvie Inc. |
Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
|
|
US9856319B2
(en)
|
2012-12-28 |
2018-01-02 |
Abbvie Inc. |
Monovalent binding proteins
|
|
MX2015012562A
(es)
*
|
2013-03-15 |
2016-06-21 |
Abbvie Inc |
Purificacion de conjugados anticuerpo-farmaco (cafs).
|
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
|
JP6693872B2
(ja)
|
2013-07-25 |
2020-05-13 |
シトムクス セラピューティクス，インコーポレイティド |
多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
|
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
AU2014358191B2
(en)
|
2013-12-04 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
|
|
CA2935423C
(en)
|
2014-01-24 |
2023-11-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to pd-1 and uses thereof
|
|
AU2015210750B2
(en)
|
2014-01-31 |
2020-08-20 |
Children's Medical Center Corporation |
Antibody molecules to TIM-3 and uses thereof
|
|
CN106535889A
(zh)
|
2014-02-10 |
2017-03-22 |
帕塔拉制药有限责任公司 |
用于治疗肺疾病的肥大细胞稳定剂
|
|
CA2938994A1
(en)
|
2014-02-10 |
2015-08-13 |
Patara Pharma, LLC |
Inhalable formulations of sodium cromolyn with improved bioavailability
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
WO2016014974A2
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
WO2016040882A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of egfr inhibitors
|
|
AU2015342961B2
(en)
|
2014-11-05 |
2021-08-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
|
US10265296B2
(en)
|
2015-08-07 |
2019-04-23 |
Respivant Sciences Gmbh |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
|
EP3331522A1
(en)
|
2015-08-07 |
2018-06-13 |
Patara Pharma LLC |
Methods for the treatment of mast cell related disorders with mast cell stabilizers
|
|
KR20250057128A
(ko)
|
2015-12-30 |
2025-04-28 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
MA45280B1
(fr)
|
2016-03-02 |
2021-08-31 |
Eisai R&D Man Co Ltd |
Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
EP3506893A4
(en)
|
2016-08-31 |
2020-01-22 |
Respivant Sciences GmbH |
CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS
|
|
AU2017339366A1
(en)
|
2016-10-07 |
2019-04-11 |
Respivant Sciences Gmbh |
Cromolyn compositions for treatment of pulmonary fibrosis
|
|
WO2019051102A2
(en)
|
2017-09-08 |
2019-03-14 |
Maverick Therapeutics, Inc. |
Constrained conditionally activated binding proteins
|
|
US12071476B2
(en)
|
2018-03-02 |
2024-08-27 |
Kodiak Sciences Inc. |
IL-6 antibodies and fusion constructs and conjugates thereof
|
|
IL317002A
(en)
|
2018-08-10 |
2025-01-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CD137 antigen binding molecule and use thereof
|
|
WO2020181140A1
(en)
|
2019-03-05 |
2020-09-10 |
Maverick Therapeutics, Inc. |
Constrained conditionally activated binding proteins
|
|
BR112021022682A2
(pt)
|
2019-05-14 |
2022-02-22 |
Provention Bio Inc |
Métodos e composições para prevenir diabetes do tipo 1
|
|
US12410238B2
(en)
|
2019-06-19 |
2025-09-09 |
Icahn School Of Medicine At Mount Sinai |
Monoclonal antibodies against JC virus
|
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CN115485300A
(zh)
|
2020-02-26 |
2022-12-16 |
索伦托药业有限公司 |
具有通用掩蔽部分的可活化的抗原结合蛋白
|
|
US11338016B2
(en)
|
2020-05-20 |
2022-05-24 |
Howard University |
C-terminal fragment of tetanus toxin (Hc) for treatment of depression
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
TW202228775A
(zh)
|
2020-10-14 |
2022-08-01 |
美商維里迪恩醫療股份有限公司 |
用於治療甲狀腺眼病之組合物及方法
|
|
JP2023553209A
(ja)
*
|
2020-12-15 |
2023-12-20 |
バイカラ セラピューティクス インコーポレイテッド |
融合タンパク質の医薬製剤
|
|
CN113354715B
(zh)
*
|
2021-05-07 |
2023-03-17 |
暨南大学 |
Egfr的改造的结合蛋白及其应用
|
|
CN113234165B
(zh)
*
|
2021-05-07 |
2023-02-28 |
暨南大学 |
EpCAM的改造的结合蛋白及其应用
|
|
WO2022251253A1
(en)
|
2021-05-24 |
2022-12-01 |
Provention Bio, Inc. |
Methods for treating type 1 diabetes
|
|
TW202320850A
(zh)
|
2021-08-10 |
2023-06-01 |
美商維里迪恩醫療股份有限公司 |
用於治療甲狀腺眼病之組合物、劑量及方法
|
|
CA3237844A1
(en)
|
2021-11-15 |
2023-05-19 |
Systimmune, Inc. |
Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
|